Compare Mongodb Inc (MDB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Sanofi SA — how do they compare? Mongodb Inc trades at $440 (market cap $35.32B), while Sanofi SA trades at $43.55 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3× Mongodb Inc's market cap, and Sanofi SA pays a 5.55% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | SNY | |
|---|---|---|
Market Cap | $35.32B | $104.30B |
Sector | Technology | Health |
52-Week High | $440.25 | $52.34 |
52-Week Low | $204.37 | $41.33 |
Enterprise Value | $32.93B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $416.67, up 4.48% in the last session, with a bullish technical setup per moving averages and ADX. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and strong analyst sentiment, with 82% buy ratings, support optimism. The stock is near its pivot point of $412, with resistance at $428.
Outlook: MDB's growth trajectory and AI-driven demand present upside, but profitability concerns and high valuation multiples (P/S 13.73) pose risks. Investors should weigh revenue momentum against persistent losses and competitive pressures in the database software market.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
